CD103, also known as integrin, alpha-E (ITGAE) binds integrin beta 7 (β7-ITGB7) to form the complete heterodimeric integrin molecule alphaEβ7. The nondepleting CD103 monoclonal antibody, M290, binds a discrete and stable subset of human CD8+ cytotoxic T lymphocytes. Expression by these cells is initiated and maintained by bioactive TGF-β. Anti-CD103-SAP recognizes and eliminates cells expressing CD103. Elimination of cells expressing CD103 can help identify the role of integrin in promoting organ allograft rejection and in graft-versus-host disease.
Anti-CD103-SAP specifically eliminates cells that express CD103 in mouse.
To view protocol(s) for this and other products please visit: www.ATSbio.com/support/protocols